Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Renal Insufficiency, Chronic 1Kidney Neoplasms 1Heart Failure 1Cardiotoxicity 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Doxorubicin 5Cyclophosphamide 3Trastuzumab 2Docetaxel 2Dexrazoxane 2empagliflozin 1Taxes 1Tamoxifen 1Razoxane 1Radiotherapy 1Radiation 1Paclitaxel 1Neoadjuvant Therapy 1Methotrexate 1Metformin 1Leucovorin 1High-Intensity Interval Training 1Hematologic Tests 1Filgrastim 1Exercise 1Epirubicin 1Echocardiography 1Cisplatin 1Chemotherapy, Adjuvant 1Carvedilol 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Cardiotoxicity × empagliflozin × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡